Abstract
BackgroundHematologic malignancies and their treatments are recognized for their significant long-term adverse effects on health-related quality of life. As a part of cancer treatment, physical exercise is known to improve physical functioning, but there are still questions regarding its impact on psychological and emotional functioning. Nonetheless, heart rate variability biofeedback (HRVB) is recognized for its positive effects on autonomic nervous system balance and emotional self-regulation. The Adapted Physical Activity and Cardiac Coherence in Hematologic Patients (APACCHE) protocol is a randomized, controlled superiority trial designed to evaluate the effects of HRBV training combined with an adaptive physical activity (APA) program compared to APA alone on the post-treatment quality of life of adult hematologic patients.MethodsSeventy patients aged 18–70 years, with various forms of hematological malignancies, in post-treatment remission within six months prior to beginning the study and who have been prescribed APA by a hematologist, will be randomly allocated in a 1:1 ratio to two 12-week treatment groups: HRVB + APA versus APA alone. APA sessions will consist of aerobic and resistance training for 1-h twice weekly. The HRVB training will consist of controlled breathing exercises with biofeedback of heart rate variability for 10 sessions and will include a daily home-based practice. The primary outcome will be to evaluate health-related quality of life (QLQ-C30, SF-36). The secondary outcomes will be to evaluate fatigue (MFI-20); anxiety and depression (HADS); clinical status with blood pressure, progression-free survival, overall survival, and body mass index; heart rate variability level and cardiac coherence score. All of these assessments will be evaluated initially (T1), 6 weeks after (T2), at the end of the 12 weeks (T3), and then at a 12-week post-intervention follow-up (T4).DiscussionTo our knowledge, this is the first protocol to investigate the additional value of HRVB on physical exercise. In addition, there has been no study previously published about HRVB in hematologic patients. We hypothesize that overall quality of life and psychological and physical functioning will be improved, potentially offering a better understanding of supportive cancer care in hematology and inferring new perspectives in psychophysiological research in cancer.Trial registrationCurrent randomized controlled trial was registered 29 November 2017 on Clinical Trials.gov (NCT number: NCT03356171).
Highlights
Hematologic malignancies and their treatments are recognized for their significant long-term adverse effects on health-related quality of life
We hypothesize that overall quality of life and psychological and physical functioning will be improved, potentially offering a better understanding of supportive cancer care in hematology and inferring new perspectives in psychophysiological research in cancer
For study participants who will be included in the experimental group, a clear description about heart rate variability biofeedback (HRVB) training will be given by the adaptive physical activity (APA) instructor
Summary
Hematologic malignancies and their treatments are recognized for their significant long-term adverse effects on health-related quality of life. Hematologic patients Hematologic cancers are heterogeneous diseases, defined by hematopoietic myeloid or lymphoid cell tumors, originating from the bone marrow or the lymphatic system [1]. They include numerous different diagnostics, according to the 2008 World Health Organization classifications [2] and their revised criteria in 2016 [3], from indolent and chronic lymphoid tumors to rapidly aggressive acute leukemia. Patients were found to have higher fatigue, dyspnea and insomnia compared to the general population [6] These symptoms are known to negatively affect physical and cognitive functioning and general quality of life [6]. Persistent psychological and social problems related to self-image, distress, isolation, and fear about the future or relapse are experienced by most patients undergoing HSCT [12]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.